If President Trump's threat to impose tariffs on pharmaceutical products goes through, it would have severe consequences for ...

Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single ...

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Billionaire hedge‑fund manager Bill Ackman is declaring an ideological victory after President Trump’s latest Truth Social ...

Pharmaceutical company Organon (NYSE:OGN) reported Q1 CY2025 results , but sales fell by 6.7% year on year to $1.51 billion.

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...